Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus® insulin glargine in patients with type 1 or type 2 diabetes mellitus

AIMS: To compare the immunogenicity profiles and the potential effects on clinical outcomes of LY2963016 insulin glargine (LY IGlar) and Lantus® insulin glargine (IGlar), products with identical primary amino acid sequences, in patients with type 1 or type 2 diabetes mellitus (T1DM or T2DM). METHODS...

Descripción completa

Detalles Bibliográficos
Autores principales: Ilag, L. L., Deeg, M. A., Costigan, T., Hollander, P., Blevins, T. C., Edelman, S. V., Konrad, R. J., Ortmann, R. A., Pollom, R. K., Huster, W. J., Zielonka, J. S., Prince, M. J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Blackwell Publishing Ltd 2016
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737399/
https://www.ncbi.nlm.nih.gov/pubmed/26434665
http://dx.doi.org/10.1111/dom.12584

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4737399/
https://www.ncbi.nlm.nih.gov/pubmed/26434665
http://dx.doi.org/10.1111/dom.12584

Ejemplares similares